Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer

Philip Q. Bao, Ramesh K. Ramanathan, Alyssa Krasinkas, Nathan Bahary, Barry C. Lembersky, David L. Bartlett, Steven J. Hughes, Kenneth K. Lee, A. James Moser, Herbert J. Zeh

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Background: There is currently no consensus about the most effective adjuvant therapy for adenocarcinoma of the pancreas. Both gemcitabine and erlotinib have been demonstrated to improve survival in patients with metastatic disease. This study was designed to evaluate the efficacy of gemcitabine and erlotinib as adjuvant therapy, and to explore potential biomarkers associated with response. Methods: An institutional review board-approved singlecenter phase II trial of adjuvant biweekly fixed-dose rate gemcitabine (1500 mg/m 2) and daily erlotinib (150 mg/ day) for 4 months followed by maintenance erlotinib (150 mg/day) over 8 months was initiated. Primary end point was recurrence-free survival (RFS). Epidermal growth factor receptor (EGFR) expression in the resected tumors was assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Results: The study completed planned accrual of 25 patients. Median follow-up was 18.2 (range 11.6-23.5) months. Recurrences were observed in 17 subjects (68%). Median RFS was 14.0 months (95% confidence interval [95% CI], 8.2-24.5) with 1-year and 2-year RFS of 56% (95% CI, 35-73) and 26% (95% CI, 6-52), respectively. Median overall survival was not reached. Estimated 1-year and 2-year overall survival was 84% (95% CI, 63-94) and 53% (95% CI, 22-76), respectively. Nine patients (36%) had a grade 3 event and only 1 (4%) had a grade 4 (neutropenia). Most toxicities were dermatologic, gastrointestinal, and constitutional. There were nonsignificant trends to longer RFS and lower recurrence rates while receiving therapy in subjects with fluorescence in situ hybridization-positive tumors and greater immunohistochemistry expression. Conclusions: Our phase II results suggest that adjuvant gemcitabine and erlotinib is a promising regimen that merits further investigation.

Original languageEnglish (US)
Pages (from-to)1122-1129
Number of pages8
JournalAnnals of surgical oncology
Volume18
Issue number4
DOIs
StatePublished - Apr 1 2011

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Bao, P. Q., Ramanathan, R. K., Krasinkas, A., Bahary, N., Lembersky, B. C., Bartlett, D. L., Hughes, S. J., Lee, K. K., Moser, A. J., & Zeh, H. J. (2011). Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Annals of surgical oncology, 18(4), 1122-1129. https://doi.org/10.1245/s10434-010-1401-9